TME Pharma N.V.
Save
7.07M
Market cap
–
Current P/E
1.07x
Forward P/E
About
Health care
Sector
Biotechnology
Industry
TME Pharma N. V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma.
Similar securities
Based on sector and market capitalization
Report issue